Trastuzumab Deruxtecan in HER2-Mutant Non-Small-Cell Lung Cancer
2021-01-07 22:09BobLietal
四川生理科學(xué)雜志 2021年7期
Bob T Li,et al.
Trastuzumab deruxtecan showed durable anticancer activity in patients with previously treated HER2-mutant NSCLC.The safety profile included interstitial lung disease that was fatal in two cases.
- 四川生理科學(xué)雜志的其它文章
- Flaviviruses Hit a Moving Target
- Binding and molecular basis of the bat coronavirus RaTG13 virus to ACE2 in humans and other species
- Systematic analysis of binding of transcription factors to noncoding variants
- Spontaneous Chitin Accumulation in Airways and Age-Related Fibrotic Lung Disease
- Meta-analysis of tumor-and T cell-intrinsic mechanisms of sensitization to checkpoint inhibition
- Emergence of an early SARS-CoV-2 epidemic in the United States